PRESS RELEASE: Psychopharmacology Publishes Mixed Evaluation of Part 2 Medical Trials of MDMA-Assisted Psychotherapy for PTSD


Written on .

PRESS RELEASE: Psychopharmacology Publishes Mixed Evaluation of Part 2 Medical Trials of MDMA-Assisted Psychotherapy for PTSD

Brad Burge, Director of Strategic Communications, MAPS
This e mail deal with is being protected against spambots. You want JavaScript enabled to view it.

Right this moment, the general outcomes of six Part 2 medical trials of MDMA-assisted psychotherapy for the therapy of posttraumatic stress dysfunction (PTSD) had been printed within the peer-reviewed journal Psychopharmacology. The paper is probably the most complete evaluation but printed of analysis into the efficacy and security of MDMA-assisted psychotherapy for PTSD.
Sponsored by the non-profit Multidisciplinary Affiliation for Psychedelic Research (MAPS), the double-blind, placebo-controlled trials in 103 topics complete discovered that 54% of members within the lively therapy group (75-125 mg MDMA) didn’t qualify for a analysis of PTSD, in comparison with 23% within the management group (0-40 mg MDMA). Within the printed evaluation, the course of double-blind therapy included two eight-hour MDMA-assisted psychotherapy periods spaced three to 5 weeks aside, mixed with weekly non-drug psychotherapy periods.
The trials had been performed by unbiased investigators in Charleston, South Carolina (two trials); Boulder, Colorado; Vancouver, British Columbia; Soluthurn, Switzerland; and Beer Yaakov, Israel. Trial members included women and men with power, treatment-resistant PTSD from all kinds of causes.
“Past the promising outcomes of the person trials, combining knowledge throughout these six trials into a bigger evaluation offers us even better confidence that the therapy results will apply to different individuals with PTSD,” stated Alli Feduccia, Ph.D., Medical Information Scientist for MAPS Public Profit Company. “We even have a greater understanding of the potential unwanted side effects of MDMA when mixed with remedy after learning the security outcomes from over 100 members.”
The mixed evaluation reveals an appropriate danger profile for MDMA, with probably the most ceaselessly reported opposed reactions throughout experimental periods being nervousness, headache, fatigue, jaw clenching, and lack of urge for food. Antagonistic reactions following therapy included nervousness and depressed temper. Momentary elevations in pulse, blood stress, and temperature had been additionally recorded throughout MDMA periods, and didn’t require medical intervention. There have been no surprising opposed reactions.
Based mostly on these outcomes, in August 2017, the U.S. Meals and Drug Administration (FDA) granted Breakthrough Remedy Designation to MDMA-assisted psychotherapy for PTSD, acknowledging that it “might show substantial enchancment over current therapies” and agreeing to expedite its improvement and evaluate.
The primary of two Part Three medical trials of MDMA-assisted psychotherapy for PTSD started enrolling members in November 2018, and can enroll 100-150 volunteers throughout 15 websites within the U.S., Canada, and Israel. The second trial will happen after an interim evaluation of the information from the primary trial, and can enroll an extra 100-150 members. European trials are deliberate to start out in 2019.
If the Part Three trials show important efficacy and an appropriate security profile, FDA approval is predicted by 2021. As soon as authorised, MDMA-assisted psychotherapy shall be out there by prescription in supervised therapeutic settings from specifically educated psychological well being suppliers.
Almost 4% of all individuals worldwide will undergo from PTSD throughout their lifetime, and over 8% within the U.S. PTSD generally is a debilitating dysfunction, with signs together with intrusive ideas and recollections, unfavorable results on pondering and temper, hyperarousal and reactivity, and avoidance. Folks with PTSD can expertise a lot decrease high quality of life and relationships, associated psychological well being circumstances, and suicidality.
The Psychopharmacology article was authored by Michael Mithoefer, M.D., Allison Feduccia, Ph.D., Lisa Jerome, Ph.D., Ann Mithoefer, B.S.N., Mark Wagner, Ph.D., Zach Walsh, Ph.D., Scott Hamilton, Ph.D., Berra Yazar-Klosinski, Ph.D., Amy Emerson, B.A., and Rick Doblin, Ph.D.
About MAPS 
Based in 1986, MAPS is a 501(c)(3) non-profit analysis and academic group that develops medical, authorized, and cultural contexts for individuals to learn from the cautious makes use of of psychedelics and marijuana. Since its founding, MAPS has raised over $70 million for psychedelic remedy and medical marijuana analysis and schooling. For extra info, go to
MAPS-sponsored medical trials are performed by the MAPS Public Profit Company (MPBC), a completely owned subsidiary of MAPS shaped in 2014 for the particular objective of balancing social advantages with earnings from authorized gross sales of MDMA, different psychedelics, and marijuana. For extra info, go to
Extra Info

  • Full paper (open entry) printed in Psychopharmacology
  • Unbiased article with extra background on the examine




Supply hyperlink

اترك تعليقاً

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *